Zobrazeno 1 - 10 of 215 pro vyhledávání: '"V. Larocca"'
1
Akademický článek
Microalgae Valorisation via Accelerated Solvent Extraction: Optimization of the Operative Conditions
Autor: A. Molino, J. Rimauro, P. Casella, A. Cerbone, V. Larocca, D. Karatza, E. Hristoforou, S. Chianese, D. Musmarra
Publikováno v: Chemical Engineering Transactions, Vol 65 (2018)
The valorisation of microalgae for the production of valuable biomolecules, for their use in several fields, such as cosmetic, pharmaceutical and animal food, by applying technologies able to avoid any kind of alteration of the biomolecule, is becomi
Externí odkaz: https://doaj.org/article/2387bb3a9a5a45cbb252bdbe5ffdb3d2
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Phase 2 Study of AV-GBM-1 (a Tumor-initiating Cell Targeted Dendritic Cell Vaccine) in Newly Diagnosed Glioblastoma Patients: Safety and Efficacy Assessment
Autor: Daniela A. Bota, Thomas H. Taylor, David E. Piccioni, Christopher M. Duma, Renato V. LaRocca, Santosh Kesari, Jose A. Carrillo, Mehrdad Abedi, Robert D. Aiken, Frank P. K. Hsu, Xiao-Tang Kong, Candace Hsieh, Peter G. Bota, Gabriel I. Nistor, Hans S. Keirstead, Robert O. Dillman
Publikováno v: Journal of experimental & clinical cancer research : CR, vol 41, iss 1
Background Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-G
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d452687f27f51d3fa6d821c2d61a207
https://doi.org/10.21203/rs.3.rs-2117699/v1
Zobrazit plný text záznamu
5
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Autor: Daniela A, Bota, Thomas H, Taylor, David E, Piccioni, Christopher M, Duma, Renato V, LaRocca, Santosh, Kesari, Jose A, Carrillo, Mehrdad, Abedi, Robert D, Aiken, Frank P K, Hsu, Xiao-Tang, Kong, Candace, Hsieh, Peter G, Bota, Gabriel I, Nistor, Hans S, Keirstead, Robert O, Dillman
Publikováno v: Journal of experimentalclinical cancer research : CR. 41(1)
Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 admini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3a82c796525cbb2bba604a43a9400b57
https://pubmed.ncbi.nlm.nih.gov/36517865
Zobrazit plný text záznamu
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Multifocal intradural extramedullary ependymoma, MYCN amplified: illustrative case
Autor: Lisa B. E. Shields, David A. Sun, Hilary A. Highfield, Renato V. LaRocca, Aaron C. Spalding, Kaylyn D. Sinicrope, Yi Ping Zhang, Christopher B. Shields
Publikováno v: Journal of Neurosurgery: Case Lessons. 3
BACKGROUND Ependymomas are the most frequent tumors of the adult spinal cord, representing 1.9% of all central nervous system tumors and 60% of spinal cord tumors. Spinal ependymomas are usually solitary, intramedullary lesions. While intradural extr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84e786ae79391d9d0157df465921a43f
https://doi.org/10.3171/case22141
Zobrazit plný text záznamu
10
CTIM-33. PHASE II TRIAL OF VACCINE IMMUNOTHERAPY IN PRIMARY GLIOBLASTOMA: ADJUNCTIVE AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE FROM IRRADIATED SELF-RENEWING AUTOLOGOUS TUMOR CELLS (AV-GBM-1)
Autor: Renato V. LaRocca, Robert O Dillman, Gabriel Nistor, Mehrdad Abedi, Jose Carrillo, Thomas H. Taylor, Frank P.K. Hsu, Christopher Duma, Robert Aiken, Santosh Kesari, David Piccioni, Candace Hsieh, Xiao-Tang Kong, Daniela A. Bota
Publikováno v: Neuro Oncol
Neuro-Oncology, vol 23, iss Supplement_6
In primary glioblastoma (GBM), overall survival (OS) is poor despite standard aggressive therapy. Adjunctive AV-GBM-1 vaccine immunotherapy may improve OS. In this multi-institutional phase II trial, key eligibility criteria for intent-to-treat (ITT)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bc93a34830b30cc812ef84e13606b8
https://europepmc.org/articles/PMC8598812/
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje